Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023699 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00023699: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00023699 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00023699, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00023699 record still lists
NCT00023699 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00023699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00023699 about?
NCT00023699 is a clinical study titled "Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or persistent...
What is the current status of trial NCT00023699?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00023699?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00023699?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia